跳至主要内容
临床试验/NCT00443144
NCT00443144已完成不适用

D3-Growth Hormone Receptor Polymorphism and Total Effect of Recombinant Human Growth Hormone on Growth in Girls With Turner Syndrome

University Hospital Tuebingen1 个研究点 分布在 1 个国家开始时间: 2005年5月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
试验地点
1

研究概览

简要总结

The protein polymorphism of the growth hormone receptor characterized by the genomic deletion of exon 3 has been linked to the magnitude of the first-year-growth response to growth hormone (GH) in girls with Turner syndrome.

Objective: to study the long-term effect of GH therapy in Turner syndrome in correlation to this GHR polymorphism in a mainly retrospective design (chart-review).

研究设计

研究类型
Observational

入排标准

年龄范围
38 Months 至 14 Years(Child)
性别
Female
接受健康志愿者

入选标准

  • Turner syndrome defined by a structural aberration or lack of the X chromosome.
  • Growth velocity less than 2 cm/year at the time of final analysis (= final height).

排除标准

  • Age <3.5 or >14 years at start of GH therapy,
  • GH peak serum levels < 8 ng/ml in two independent tests,
  • Thelarche at start or during the first year of treatment,
  • Oxandrolone therapy for any time and a duration of GH therapy less than 2 years.

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Gerhard Binder

Pediatric Endocrinology

University Hospital Tuebingen

研究点 (1)

Loading locations...

相似试验